Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OT

WKN: A40F8P | ISIN: US68764Y2072 | Ticker:
NASDAQ
18.11.26 | 21:58
0,913 US-Dollar
+0,32 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OS THERAPIES INC Chart 1 Jahr
5-Tage-Chart
OS THERAPIES INC 5-Tage-Chart

Aktuelle News zur OS THERAPIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOS Therapies: OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company427OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029Company continues to benefit from its UK research...
► Artikel lesen
12.11.OS Therapies erhält Mehrwertsteuerrückerstattung und gibt Update zu FDA-Voucher-Programmen1
12.11.OS Therapies Inc - 8-K, Current Report-
10.11.OS Therapies: OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma368US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice MeetingSubmission expected to be accepted in the fourth quarter of 2026Potential early...
► Artikel lesen
05.11.OS Therapies: OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial330Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K's MHRA for Early Commercial Access and Trial AuthorisationGrasonville, Maryland--(Newsfile Corp. - November 5, 2026)...
► Artikel lesen
OS THERAPIES Aktie jetzt für 0€ handeln
19.10.OS Therapies Inc - 8-K, Current Report3
19.10.OS Therapies: OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million706Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market...
► Artikel lesen
07.10.OS Therapies: OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma547Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc....
► Artikel lesen
06.10.OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment1
06.10.OS Therapies: OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial676Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p...
► Artikel lesen
05.10.OS Therapies Inc - 8-K, Current Report1
01.10.OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO2
01.10.OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer590Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile...
► Artikel lesen
24.09.OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)561New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based...
► Artikel lesen
21.09.OS Therapies: OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis850Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing...
► Artikel lesen
17.09.OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program858FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize...
► Artikel lesen
15.09.OS Therapies: OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing561Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in...
► Artikel lesen
09.09.OS Therapies Inc - 8-K, Current Report1
08.09.OS Therapies Reports Strong Survival Data for Bone Cancer Treatment1
08.09.OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial58771.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from...
► Artikel lesen
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1